4D Molecular Therapeutics (FDMT) PT Raised to $38 at Chardan, 'Phase II wAMD Data Set Up a Competitive GT Profile'
Tweet Send to a Friend
(Updated - February 5, 2024 10:14 AM EST)
Chardan Capital Markets analyst Geulah Livshits raised the price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Chardan Capital Markets analyst Geulah Livshits raised the price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
